Premium
Multibiomarker analysis in patients with acute myocardial infarction
Author(s) -
Schernthaner Christiana,
Lichtenauer Michael,
Wernly Bernhard,
Paar Vera,
Pistulli Rudin,
Rohm Ilonka,
Jung Christian,
Figulla HansReiner,
Yilmaz Attila,
Cadamuro Janne,
HaschkeBecher Elisabeth,
Pernow John,
Schulze Paul Christian,
Hoppe Uta C.,
Kretzschmar Daniel
Publication year - 2017
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.12785
Subject(s) - medicine , myocardial infarction , cardiology , gdf15 , ejection fraction , creatine kinase , coronary artery disease , acute coronary syndrome , gastroenterology , heart failure
Background Novel biomarkers representing different pathobiological pathways and their role in patients with acute myocardial infarction ( AMI ) were studied. Methods We retrospectively analysed serum levels of soluble suppression of tumorigenicity ( sST 2), growth‐differentiation factor‐15 ( GDF ‐15), soluble urokinase plasminogen activator receptor (su PAR ), heart‐type fatty acid‐binding protein (H‐ FABP ) and plasma fetuin A in blood of patients with AMI ( STEMI , n = 61; NSTEMI , n = 57) compared to controls with excluded coronary artery disease ( n = 76). Furthermore, detailed correlation analysis was performed. Results Compared with controls, in patients with STEMI and NSTEMI higher levels expressed as median of sST 2 in pg/mL ( STEMI : 13210·9, NSTEMI : 11989·1, control: 5248; P < 0·001), GDF ‐15 in pg/mL ( STEMI : 818·8, NSTEMI 677·5, control 548·6; P < 0·001), su PAR in pg/mL ( STEMI : 3461·1, NSTEMI : 3466·7, control: 2463·6; P < 0·001), H‐ FABP in ng/mL ( STEMI : 5·8, NSTEMI : 5·4, control: 0·0; P < 0·001) and lower plasma fetuin A levels in μg/mL ( STEMI : 95, NSTEMI : 54, control: 116·6; P < 0·001) were detected. Correlation analysis found clinical and biochemical parameters such as ejection fraction, length of hospital stay, creatine kinase, NT ‐pro BNP and hs Troponin T levels as well as inflammatory markers ( CRP , leucocytes) to be significantly correlated with novel biomarkers. Conclusion Plasma levels of novel biomarkers were significantly elevated ( sST 2, GDF ‐15, H‐ FABP , su PAR ) or inversely downregulated (fetuin A) in patients with AMI compared to a control group with excluded coronary artery disease. Significant correlations with various clinical parameters and standard biochemical markers were found.